Category - Developments

Developments

Aridis Pharma gets EMA orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF). AR-501 is an inhaled...

July 19, 2019

Developments

InflaRx IFX-1 misses primary endpoint in Phase 2b hidradenitis suppurativa trial

InflaRx (NASDAQ:IFRX) reported that IFX-1 missed its primary endpoint in a Phase 2b trial in hidradenitis suppurativa (HS) patients. HS a chronic inflammatory skin disease that causes abscesses and scarring. IFX-1 is a...

July 19, 2019

Developments

Alphatec launches titanium interbody implant for spinal fusion surgeries

Alphatec Holdings (NASDAQ:ATEC) launched its IdentiTi porous titanium interbody implant system for anterior lumbar interbody fusion procedures. Key features of the implant include a stiffness similar to bone, reduced...

July 19, 2019

Developments

BeyondSpring prices $35-million equity offering

BeyondSpring (NASDAQ:BYSI) priced a public offering of 2,058,825 ordinary shares at $17 apiece for expected gross proceeds of $35-million. The offering was led by Decheng Capital. The underwriter has a 30-day option to...

July 17, 2019

Developments

Theralase receives notice of acceptance for Multiwavelength PDT from Russian Patent Office

The Russian Patent Office issued a notice of acceptance for Theralase Technologies’ (TSXV:TLT) (OTCQB:TLTFF) Multiwavelength photodynamic therapy (PDT) patent application. The patent application will issue into a patent...

July 16, 2019

Developments

Imagin Medical updates i/Blue’s functional unit development

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) provided an update on its progress towards verifying the i/Blue imaging system’s functional prototype. The company has integrated the i/Blue...

July 15, 2019

Developments

Kadmon Holdings doses first patient in Phase 2 systemic sclerosis trial

Kadmon Holdings (NYSE:KDMN) dosed the first patient in its Phase 2 clinical trial of KD025 in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a chronic immune disease characterized by fibrosis of the...

July 11, 2019

Developments

GMP adds Zenabis Global to Best Ideas list

GMP Securities added Zenabis Global (TSX:ZENA) to its Best Ideas list, saying its sees the company becoming a top five Canadian licensed producer of cannabis but with a valuation well below most of its peers. Analyst...

July 10, 2019

Developments

Profound Medical sells first TULSA-PRO system in Japan

Profound Medical (TSX:PRN; OTCQX:PRFMF) sold its first TULSA-PRO system to Hokuyu Hospital in Sapporo through Japan’s Pharmaceutical and Medical Device (PMD) Act’s expanded access program. Japan’s Pharmaceutical...

July 10, 2019

Developments

Trovagene initiates Phase 1b/2 trial of ovansertib in colorectal cancer

Trovagene (NASDAQ:TROV) began enrollment for its Phase 1b/2 study of onvansertib for the treatment of patients with metastatic colorectal cancer (mCRC). The trial will assess the safety and efficacy of onvansertib, in...

July 9, 2019

Category - Developments

Aridis Pharma gets EMA orphan drug designation for CF drug

InflaRx IFX-1 misses primary endpoint in Phase 2b hidradenitis suppurativa trial

Alphatec launches titanium interbody implant for spinal fusion surgeries

BeyondSpring prices $35-million equity offering

Theralase receives notice of acceptance for Multiwavelength PDT from Russian Patent Office

Imagin Medical updates i/Blue’s functional unit development

Kadmon Holdings doses first patient in Phase 2 systemic sclerosis trial

GMP adds Zenabis Global to Best Ideas list

Profound Medical sells first TULSA-PRO system in Japan

Trovagene initiates Phase 1b/2 trial of ovansertib in colorectal cancer

General

More